contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vistin-pharma-asa-notice-of-annual-general-meeting-22-may-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Vistin Pharma är ett norskt läkemedelsbolag. Bolaget bedriver forskning och utveckling samt vidare produktion av farmaceutiska substanser (API), främst substanserna metformin, kodein fosfat och folkodin. Substanserna används huvudsakligen vid behandling av diabetes. Bolaget är verksamt på global nivå, med störst närvaro på den nordiska marknaden. Vistin Pharma grundades 2015 och har sitt huvudkontor i Oslo.

Vistin Pharma

Oslo, Norway, 29 April 2025 Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 22 May 2025 at 13:00 CEST. A physical...

Oslo, Norway, 29 April 2025 Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 22 May 2025 at 13:00 CEST. A physical Annual General Meeting will not be held. Instead, shareholders should authorize the Chairman of the Board. It is possible to give proxy with and without voting instructions. By using a proxy with voting instructions, the shareholders will vote on the specific issues without personal attendance. For further information on the use of proxy, see general information at the bottom of the notice and enclosed proxy forms. The recommendation from the Election Committee is attached the notice and available on the Company's website. The formal call will be sent to all shareholders registered in the Norwegian Central Security Depository (VPS) and are also attached to this announcement. For further information, please contact: Alexander Karlsen CFO +47 97 05 36 21 <a href="https://www.globenewswire.com/Tracker?data=nI6UbARVvB57SJSLgEATuiT-p46uCCRSLbyGsDx7yqOYEjSW-ol6-DF1SQvzYzX3W3AWStFk7VMNXMxZU6Nbn4Tw22C7MTn-6VWKMPaWaGyW6GTRcAGJV4eUZTD_OtXO">alexander.karlsen@vistin.com</a> This information is subject to the disclosure requirements pursuant to section&nbsp;5-12 of the Norwegian Securities Trading Act. &nbsp; &nbsp; Attachments<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/b59eacba-d34b-4387-be93-0dd649b9073d">Vistinpharmaasa-2024-12-31-0-en</a> </li> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/3fb2d5d2-4622-4d42-a1c1-98f00d1d4d8c">2025 03 13 Vistin Pharma election committee proposal</a> </li> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/2030ff1f-8b6d-4929-b604-11dbafa3bfea">Annual Report 2024 Vistin Pharma ASA</a> </li> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/0b3f5cc4-cf52-43f3-806f-98253d833b94">Remuneration policy for salary and other remuration for executive management and board members_Vistin Pharma ASA</a> </li> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/f81a08a1-a326-4fe4-ad37-92eb20423de4">Call for annual general meeting 22 May 2025 Vistin Pharma ASA</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTA5MzE1MSM0MDIxMzE4NjIjMjAxODc1NA==" alt=""> <img src="https://ml-eu.globenewswire.com/media/NmM2NzFjODItYTkxMi00MGQ4LTk3MjctNDNmNjJlM2UzMWIwLTEwMzAzMjctMjAyNS0wNC0yOS1lbg==/tiny/Vistin-Pharma-ASA.png" alt="">